Inspire Medical Systems Stock (NYSE: INSP)

Dernières nouvelles pour Inspire Medical Systems (NYSE:INSP) Stock

Inspire Medical Systems

Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.

Inspire Medical Systems, Inc. Common Stock

Inspire Medical Systems Inc

Inspecs Group PLC

Insperity Inc

Inspira Technologies Oxy B.H.N. Ltd. - Ordinary Shares

Inspira Technologies Oxy BHN Ltd

Inspira Technologies Oxy B.H.N. Ltd. - Warrant

Inspirato Inc

Inspirato Incorporated - Class A Common Stock

Inspire 100 ETF

Inspire Corporate Bond ETF

Inspire Global Hope ETF

Inspire International ETF

INSPIRE SEMICONDUCTOR HLD by INSPIRE SEMICONDUCTOR HLDGS INC.

Inspire Semiconductor Holdings Inc

Inspire Small/Mid Cap ETF

Inspire Tactical Balanced ETF

Inspire Veterinary Partners, Inc. - Class A Common Stock

Inspire Veterinary Partners Inc

InspireMD Inc

Inspired Entertainment, Inc. - Common Stock

Inspired Entertainment Inc

Benchmark analyst Mark Zgutowicz maintains Wix.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WIX#NASDAQ">WIX</a>) with a Buy and raises the price target from $225 to $250.

News

Price Target

Analyst Ratings

Benchmark Maintains Buy on Wix.com, Raises Price Target to $250

On November 20, 2024, the Board of Directors of United Bancorp, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UBCP#NASDAQ">UBCP</a>) declared a fourth quarter dividend payment of $0.18 per share for shareholders of record on December 10, 2024 with a payment date of December 20, 2024. This payment is greater than the regular cash dividends paid in the first three quarters of the current year, which were $0.1725, $0.1750 and $0.1775 respectively. With this fourth quarter dividend payment and year-to-date, UBCP has paid total cash dividends of $0.8550 (inclusive of a special cash dividend of $0.15 paid in the first quarter), which is an increase of $0.04, or 4.9%, over the amount paid during the same period the previous year. At the fourth quarter payment level, the regular cash dividend produces a forward yield of 5.4% based on UBCP&#39;s market value of $13.13 at the most recent quarter-end.

Dividends

UBCP

United Bancorp Increases Its Q4 Cash Dividend Payment From $0.1775 To $0.18 Per Share

Deutsche Bank analyst Brad Zelnick maintains Snowflake (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNOW#NYSE">SNOW</a>) with a Buy and raises the price target from $180 to $190.

SNOW

Deutsche Bank Maintains Buy on Snowflake, Raises Price Target to $190

The contract gives the nation's oldest bank access to more than $3 billion in deposits a month.
 <a href="https://www.americanbanker.com/payments/news/bny-gains-treasurys-direct-express-benefits-contract" title="https://www.americanbanker.com/payments/news/bny-gains-treasurys-direct-express-benefits-contract">https://www.americanbanker.com/payments/news/bny-gains-treasurys-direct-express-benefits-contract</a>

'BNY gains Treasury's Direct Express benefits contract' - American Banker

Citigroup analyst Fatima Boolani maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $395 to $432.

PANW

Citigroup Maintains Buy on Palo Alto Networks, Raises Price Target to $432

Deutsche Bank analyst Brad Zelnick maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Buy and raises the price target from $395 to $415.

Deutsche Bank Maintains Buy on Palo Alto Networks, Raises Price Target to $415

Citigroup analyst Keith Horowitz maintains Citizens Financial Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CFG#NYSE">CFG</a>) with a Buy and raises the price target from $50 to $58.

Citigroup Maintains Buy on Citizens Financial Group, Raises Price Target to $58

&nbsp;Fox Entertainment and Hulu are staying in business together in a major way.
The two companies have struck a new multi-year content partnership that includes in-season streaming rights for Fox's programming slate.
The broadcast network and the Disney-owned streamer have also expanded their multi-platform marketing arrangement in the deal, which Deadline understands is worth more than $1.5B over four years with the ad-load included.
Fox got in early to renew the deal – the previous arrangement was unveiled in January 2023 and this new pact runs through 2029. It gives the network a bedrock to build out its slate of originals including dramas such as Rescue HI-Surf and Murder in a Small Town, comedies such as Animal Control and reality series such as The Masked Singer, The Floor and Gordon Ramsay's Next Level Chef.
<a href="https://deadline.com/2024/11/fox-hulu-streaming-deal-1236183347/" title="https://deadline.com/2024/11/fox-hulu-streaming-deal-1236183347/">https://deadline.com/2024/11/fox-hulu-streaming-deal-1236183347/</a>

FOXA

'Fox Entertainment & Hulu Extend Major Streaming Deal With Pact Worth North Of $1.5B' -Deadline

Georgia lawmakers are exploring the <a href="https://www.benzinga.com/topic/psychedelic-assisted-therapies">potential of psychedelics</a> in treating veterans' mental health challenges, marking a significant shift in the state's traditionally conservative stance on drug policy. As Medical Xpress <a href="https://medicalxpress.com/news/2024-11-georgia-lawmakers-funding-psychedelics-veterans.html">reported</a>, a bipartisan panel has recommended allocating up to $5 million to study the therapeutic effects of substances like <a href="https://www.benzinga.com/topic/mdma">MDMA</a> and <a href="https://www.benzinga.com/topic/psilocybin">psilocybin</a> on post-traumatic stress disorder (PTSD) and traumatic brain injuries in veterans.
<h3 class="wp-block-heading">A Promising, Yet Controversial Step</h3>
The recommendation is part of 16 proposals from the Senate Study Committee on Veterans, Mental Health and Housing. While funding must still be approved by the Georgia General Assembly, the panel's endorsement reflects growing interest in alternative therapies for PTSD, a condition <a href="https://www.benzinga.com/24/11/41881842/why-do-veterans-deserve-access-to-psychedelic-therapy">disproportionately affecting veterans</a>. Symptoms such as severe anxiety, nightmares, and insomnia often resist traditional treatments, leaving many searching for solutions.
"Veterans who suffer from post-traumatic stress and brain injuries have very few reliable options for treatment," said state Sen. Josh McLaurin, a Democrat from Atlanta and committee member. "A growing body of research shows that psychedelics—when administered carefully in clinical settings—may be a total game changer."
<h3 class="wp-block-heading">National Context and Growing Support</h3>
Georgia's initiative follows similar efforts in states like <a href="https://www.benzinga.com/markets/cannabis/20/11/18204455/oregon-becomes-first-us-state-to-decriminalize-drug-possession-begins-psilocybin-program">Oregon</a> and <a href="https://www.benzinga.com/markets/cannabis/24/08/40445352/colorados-psilocybin-industry-takes-off-new-rules-for-magic-mushroom-businesses">Colorado</a>, where psilocybin has been legalized, and California, which narrowly missed passing a psychedelics decriminalization bill last year. Research institutions like Atlanta's Emory University have already begun studying the therapeutic potential of psychedelics when combined with psychotherapy. Despite federal regulators <a href="https://www.benzinga.com/markets/cannabis/24/08/40300943/fda-rejects-mdma-for-ptsd-treatment-calls-for-more-research-on-psychedelic-therapy">recently denying MDMA's approval for PTSD treatment</a>, the U.S. Department of Veterans Affairs (VA) has <a href="https://www.benzinga.com/markets/cannabis/24/01/36523540/veterans-affairs-after-decades-will-fund-psychedelic-research-for-vets-with-ptsd-and-depression">signaled readiness to incorporate psychedelic therapy</a> if it gains regulatory approval.
Support for psychedelic research is also gaining momentum from influential figures like Vietnam veteran and GoDaddy founder Bob Parsons, who has invested millions into advancing the field. His advocacy has swayed skeptics like Democratic state Sen. Ed Harbison who admitted initial hesitation but now sees the potential benefits.
<h3 class="wp-block-heading">Broader Recommendations for Veterans</h3>
The committee's proposals extend beyond psychedelics, including measures to waive or reduce property taxes for returning veterans and establish programs to simplify the complexities of the healthcare system for service members.
If approved, Georgia's research funding would signal an important step toward innovative mental health treatments, offering hope to veterans seeking relief from debilitating conditions. The move reflects a broader national conversation about the role of psychedelics in addressing mental health crises.
Cover image made with AI

Cannabis

Government

Psychedelics

Health Care

Georgia Lawmakers Take First Steps Toward Psychedelic-Assisted Therapy For Veterans

Deutsche Bank analyst Corinne Blanchard maintains Sociedad Quimica Y Minera (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQM#NYSE">SQM</a>) with a Hold and lowers the price target from $35 to $31.

Deutsche Bank Maintains Hold on Sociedad Quimica Y Minera, Lowers Price Target to $31

Citigroup analyst Keith Horowitz maintains Regions Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RF#NYSE">RF</a>) with a Buy and raises the price target from $26 to $30.

Citigroup Maintains Buy on Regions Finl, Raises Price Target to $30

Deutsche Bank analyst Scott Deuschle maintains Hexcel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HXL#NYSE">HXL</a>) with a Hold and lowers the price target from $63 to $60.

Deutsche Bank Maintains Hold on Hexcel, Lowers Price Target to $60

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Markets

$BTC

SAIH

SAIHEAT Purchases $1.5M In Bitcoin, Increasing Holdings To 102 Bitcoins As Part Of Its Long-Term HODL Strategy To Strengthen Digital Asset Position

Willdan Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLDN#NASDAQ">WLDN</a>) announced today that it has won a three-year, $4.5 million contract to provide in-house building division operations and fire plan inspection review services for the City of Bellflower.

Contracts

WLDN

Willdan Selected For $4.5M Contract To Provide Building And Safety Services And Fire Plan Review For The City Of Bellflower

14 analysts have shared their evaluations of Goldman Sachs Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GS#NYSE">GS</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">11</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">8</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Goldman Sachs Gr, revealing an average target of $578.36, a high estimate of $680.00, and a low estimate of $472.00. This current average has increased by 6.57% from the previous average price target of $542.71. 
<img src="https://www.benzinga.com/files/images/story/2024/1732204845_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The perception of Goldman Sachs Gr by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Keith Horowitz</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$585.00</td>
<td>$485.00</td>
</tr>
<tr>
<td>Mike Mayo</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$680.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$661.00</td>
<td>$614.00</td>
</tr>
<tr>
<td>Jason Goldberg</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$588.00</td>
<td>$565.00</td>
</tr>
<tr>
<td>Kian Abouhossein</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$520.00</td>
<td>$472.00</td>
</tr>
<tr>
<td>Glenn Schorr</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$575.00</td>
<td>$520.00</td>
</tr>
<tr>
<td>David Konrad</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Raises</td>
<td>Outperform</td>
<td>$570.00</td>
<td>$555.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$614.00</td>
<td>$577.00</td>
</tr>
<tr>
<td>Betsy Graseck</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$570.00</td>
<td>$560.00</td>
</tr>
<tr>
<td>Ebrahim Poonawala</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$575.00</td>
<td>$563.00</td>
</tr>
<tr>
<td>Devin Ryan</td>
<td>JMP Securities</td>
<td>Raises</td>
<td>Market Outperform</td>
<td>$550.00</td>
<td>$525.00</td>
</tr>
<tr>
<td>Brennan Hawken</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$560.00</td>
<td>$550.00</td>
</tr>
<tr>
<td>Chris Kotowski</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$577.00</td>
<td>$548.00</td>
</tr>
<tr>
<td>Kian Abouhossein</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$472.00</td>
<td>$464.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Goldman Sachs Gr. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Goldman Sachs Gr compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Goldman Sachs Gr's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Goldman Sachs Gr's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/GS/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Goldman Sachs Gr analyst ratings.</a>
<h2>Unveiling the Story Behind Goldman Sachs Gr</h2>
Goldman Sachs is a leading global investment banking and asset management firm. Approximately 20% of its revenue comes from investment banking, 45% from trading, 20% from asset management and 15% from wealth management and retail financial services. Around 60% of the company's net revenue is generated in the Americas, 15% in Asia, and 25% in Europe, the Middle East, and Africa.
<h3>A Deep Dive into Goldman Sachs Gr's Financials</h3>
Market Capitalization Analysis: With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.
Positive Revenue Trend: Examining Goldman Sachs Gr's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 7.46% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: Goldman Sachs Gr's net margin is impressive, surpassing industry averages. With a net margin of 21.89%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Goldman Sachs Gr's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.59%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Goldman Sachs Gr's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.16%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Goldman Sachs Gr's debt-to-equity ratio surpasses industry norms, standing at 3.25. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Basics of Analyst Ratings</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Expert Ratings For Goldman Sachs Gr

BlackBerry Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BB#NYSE">BB</a>) said BlackBerry AtHoc is on track to become the first critical event management solution to achieve FedRAMP High Authorization. The Joint Authorization Board currently&nbsp;<a target="_blank" href="https://www.accesswire.com/945127/blackberry-athoc-in-process-finalization-for-fedramp-high-authorization" rel="noreferrer noopener">lists its status as &#8220;In Process.&#8221;</a>
BlackBerry AtHoc, trusted by over 75% of U.S. federal agencies, enables rapid crisis communication, incident response, and secure messaging while meeting top security standards.
FedRAMP High secures sensitive government data in cloud environments, protecting systems like law enforcement, health, and emergency services against severe risks to confidentiality and availability.
&#8220;Achieving FedRAMP High authorization is a significant milestone for BlackBerry AtHoc, further validating our commitment to delivering the most secure and compliant critical communications solutions for our customers. This designation positions BlackBerry AtHoc as the premiere choice for organizations that request the highest levels of security, privacy, and operational flexibility,&#8221; commented Ramon Pinero, General Manager, BlackBerry AtHoc.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/large-cap/24/11/42033411/cybersecurity-gets-a-boost-blackberry-canada-and-tmu-team-up-to-fortify-aseans-digital-defenses" rel="noreferrer noopener">Cybersecurity Gets A Boost: BlackBerry, Canada, And TMU Team Up To Fortify ASEAN&#8217;s Digital Defenses</a>
Dubhe Beinhorn, Vice President of Federal Sales and Customer Success at BlackBerry AtHoc, noted that FedRAMP High authorization will enhance AtHoc&#8217;s ability to provide customers with increased security and compliance. As cybersecurity and data privacy take center stage, AtHoc is positioned to meet evolving industry demands.
Price Action: BB shares are trading higher by 0.43% at $2.32 at the last check Thursday.

Equities

BlackBerry AtHoc Nears Key Authorization, Poised To Amplify Federal Cybersecurity And Compliance

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Omnicell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMCL#NASDAQ">OMCL</a>) in the last three months.
The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Omnicell and provided 12-month price targets. The average target is $52.0, accompanied by a high estimate of $64.00 and a low estimate of $41.00. Surpassing the previous average price target of $40.50, the current average has increased by 28.4%.
<img src="https://www.benzinga.com/files/images/story/2024/1732204832_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Omnicell. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anne Samuel</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Neutral</td>
<td>$44.00</td>
<td>$37.00</td>
</tr>
<tr>
<td>Stephanie Davis</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$58.00</td>
<td>$39.00</td>
</tr>
<tr>
<td>Matt Hewitt</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$64.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Allen Lutz</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$57.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Stan Berenshteyn</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$41.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Bill Sutherland</td>
<td>Benchmark</td>
<td>Maintains</td>
<td>Buy</td>
<td>$48.00</td>
<td>$48.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Omnicell. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Omnicell compared to the broader market.</li>
<li>Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Omnicell's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Omnicell's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/OMCL/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Omnicell analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Omnicell's Background</h2>
Omnicell Inc provides automation and business analytics software for healthcare providers. It helps its customers to define and deliver cost-effective medication management that is designed to equip and empower pharmacists and nurses to focus on patient care rather than administrative tasks, and to drive improved clinical, operational, and financial outcomes across all care settings. Omnicell generates the vast majority of its revenue in the United States.
<h3>Financial Milestones: Omnicell's Journey</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining Omnicell's financials over 3 months reveals challenges. As of 30 September, 2024, the company experienced a decline of approximately -5.44% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Omnicell's net margin is impressive, surpassing industry averages. With a net margin of 3.06%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Omnicell's ROE stands out, surpassing industry averages. With an impressive ROE of 0.71%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Omnicell's ROA excels beyond industry benchmarks, reaching 0.38%. This signifies efficient management of assets and strong financial health.
Debt Management: Omnicell's debt-to-equity ratio is below the industry average at 0.5, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: What Are They?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

OMCL

Beyond The Numbers: 6 Analysts Discuss Omnicell Stock

Agree Realty's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADC#NYSE">ADC</a>) short percent of float has risen 41.16% since its last report. The company recently reported that it has 13.97 million shares sold short, which is 17.49% of all regular shares that are available for trading. Based on its trading volume, it would take traders 10.78 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Agree Realty Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1732204831_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Agree Realty has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Agree Realty's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Agree Realty's peer group average for short interest as a percentage of float is 4.13%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

How Is The Market Feeling About Agree Realty?

Benchmark analyst Mark Zgutowicz maintains Global E Online (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLBE#NASDAQ">GLBE</a>) with a Buy and raises the price target from $45 to $60.

GLBE

Benchmark Maintains Buy on Global E Online, Raises Price Target to $60

Pyxis Tankers (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PXS#NASDAQ">PXS</a>) is set to give its latest quarterly earnings report on Friday, 2024-11-22. Here's what investors need to know before the announcement.
Analysts estimate that Pyxis Tankers will report an earnings per share (EPS) of $0.45. 
The market awaits Pyxis Tankers's announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It's important for new investors to understand that guidance can be a significant driver of stock prices.
Here's a look at Pyxis Tankers's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td></td>
<td></td>
<td>0.25</td>
<td>0.19</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.43</td>
<td>0.3</td>
<td>0.38</td>
<td>0.26</td>
</tr>
<tr>
<td>Price Change %</td>
<td>4.0%</td>
<td>-1.0%</td>
<td>2.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<h3>Stock Performance</h3>
Shares of Pyxis Tankers were trading at $4.1451 as of November 20. Over the last 52-week period, shares are down 3.31%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/PXS/earnings">To track all earnings releases for Pyxis Tankers visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings

Earnings Outlook For Pyxis Tankers

Mizuho Securities analyst Anthony Petrone has maintained their bullish stance on INSP stock, giving a Buy rating yesterday. Anthony Petrone's ratin...

Inspire Medical Systems: Strong Performance and Growth Potential Highlighted by Positive Indicators and Strategic Opportunities

Leerink Partners analyst Mike Kratky reiterated a Hold rating on Inspire Medical Systems (INSP – Research Report) on November 4 and set a price tar...

Inspire Medical Systems: Mixed Signals Lead to Hold Rating Amid Utilization and Competitive Challenges

Columbia Acorn Fund Q3 2024 Investment Commentary

Inspire Medical enters $75M accelerated share repurchase agreement

Lake Street analyst Frank Takkinen reiterated a Buy rating on Inspire Medical Systems (INSP – Research Report) today and set a price target of $270...

Lake Street Remains a Buy on Inspire Medical Systems (INSP)

Baird Q3 2024 Small/Mid Cap Growth Equity Fund Commentary

Fidelity OTC Portfolio Fund Q2 2024 Review

BofA upgraded Inspire Medical (INSP) to Buy from Neutral with a $255 price target Published first on TheFly – the ultimate source for real-time, ma...

Inspire Medical upgraded to Buy from Neutral at BofA

The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need...

Target downgraded, Chewy upgraded: Wall Street's top analyst calls

Inspire Medical upped to buy by BoA, improved margins cited

AAON

AAPL

ACLS

ALAB

ALNY

APPF

ASML

ASMLF

ATKR

AVGO

BESIY

BESVF

BOOT

BROS

BURL

BWXT

CACI

CASY

CAVA

CHDN

CHWY

CIGI

CPRI

CWAN

CYBR

EXAS

EXLS

FANG

FIVE

FOUR

FTAI

FTAIO

GOOG

GOOGL

INGM

INSP

INTC

IRTC

JKHY

KNSL

LGIH

LMND

LSCC

MANH

MEDP

MNDY

MRVL

NBIX

NFLX

NTRA

NVDA

ONTO

PCOR

PODD

POOL

PRCT

QCOM

RMBS

RXST

SEDG

SITM

SMCI

SMPL

SPXC

TARS

TECH

TOST

TREX

TSLA

TSMWF

VNOM

Press Releases

Inspire Medical Systems, Inc. Announces Second Quarter 2024 Financial Results and Updates 2024 Outlook

Inspire Medical Systems, Inc. to Present at Upcoming Investor Conferences

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Inspire Medical Systems, Inc. to Report Third Quarter 2024 Financial Results on November 4, 2024

Inspire Medical Systems, Inc. to Present at UBS Global Healthcare Conference

Inspire Medical Systems, Inc. Announces Third Quarter 2024 Financial Results and Updates 2024 Outlook

Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference

Financing

Inspire Medical Systems, Inc. Announces $75 million Accelerated Share Repurchase Program

UPDATED – Inspire Medical Systems, Inc. to Present at Jefferies London Healthcare Conference

Inspire Medical Systems, Inc. to Present at Piper Sandler 36th Annual Healthcare Conference

Comments

Inspire Medical Systems

Actualités

Dernières nouvelles pour Inspire Medical Systems (NYSE:INSP) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL